OpenLB
Open Library of Bioscience
Advanced Search
Internal and emergency medicine
Jan, 2024;19 (1): 59-70.

The global burden of lower respiratory infections attributable to respiratory syncytial virus in 204 countries and territories, 1990-2019: findings from the Global Burden of Disease Study 2019.

Min Wu, Qiong Wu, Danzhou Liu, Wu Zu, Dansi Zhang, Long Chen
Author Information
  1. Min Wu: Department of Pulmonary and Critical Care Medicine, The First Hospital of Shanxi Medical University, NHC Key Laboratory of Pneumoconiosis, Shanxi Key Laboratory of Respiratory Diseases, 030001, Taiyuan, China.
  2. Qiong Wu: Intensive Care Unit, Inner Mongolia Medical University Affiliated Hospital, 010050, Hohhot, China. qingwunm1014@163.com.
  3. Danzhou Liu: Department of Critical Care Medicine, Mining Industry Group of Liaoning Health Industry Group, General Hospital of Fuxin, 123099, Fuxin, China.
  4. Wu Zu: Department of Cardiology, Mining Industry Group of Liaoning Health Industry Group, General Hospital of Fuxin, 123099, Fuxin, China.
  5. Dansi Zhang: Department of Critical Care Medicine, Mining Industry Group of Liaoning Health Industry Group, General Hospital of Fuxin, 123099, Fuxin, China.
  6. Long Chen: Department of Critical Care Medicine, Mining Industry Group of Liaoning Health Industry Group, General Hospital of Fuxin, 123099, Fuxin, China.
PMID: 37789183 DOI: 10.1007/s11739-023-03438-x

Abstract

AIMS: The purpose of this study is to investigate the global epidemiological characteristics of lower respiratory infections (LRI) burden attributable to respiratory syncytial virus (RSV) from 1990 to 2019.
MATERIALS AND METHODS: We used the recent Global Burden of Disease Study (GBD) 2019 to systematically evaluate the current burden and temporal trend of LRI burden attributable to RSV by global, age, sex, geographic location, and socio-economic status.
RESULTS: Globally, the disability-adjusted life years (DALYs) cases of LRI attributable to RSV dropped from an estimated 39,964,488 [95% uncertainty interval (UI): 16,825, 572 to 68,800,553] in 1990 to 14,956,514 (95%UI: 6,271,751 to 25,910,753) in 2019 and estimated death cases droped from 541,172 (95%UI:226,614 to 958,596) to 338,495 (95%UI:126,555 to 667,109) from1990 to 2019. Similarly, age-standardized DALYs rate of LRI attributable to RSV decreased from an estimated 646.2 (95%UI: 276.9 to 1121.5) in 1990 to 218.3 (95%UI:92.1 to 376.8) in 2019 and estimated age-standardized deaths rate decreased from 10.3 (95%UI:4.1 to 18.5) to 4.8 (95%UI:1.8 to 9.3) between 1990 and 2019. In 2019, the highest age-standardized DALYs and death rates of LRI attributable to RSV were seen in the lower SDI regions, children and old people. From 1990 to 2019, age-standardized DALYs and death rates of LRI attributable to RSV decreased with increasing SDI.
CONCLUSIONS: In this study, we found that the LRI burden attributable to RSV decreased significantly from 1990 to 2019. However, the lower SDI regions, children and old people urgently require cost-effective interventions to prevent and reduce the LRI burden attributable to RSV.

Keywords

Deaths Disability‐adjusted life years Global Burden of Disease Study Lower respiratory infections Respiratory syncytial virus

References

  1. Mazur NI, HigginsNunes DMC, Melero JA, Langedijk AC, Horsley N et al (2018) The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Lancet Infect Dis 18(10):e295–e311. https://doi.org/10.1016/S1473-3099(18)30292-5 [DOI: 10.1016/S1473-3099(18)30292-5]
  2. Nair H, Nokes DJ, Gessner BD, Dherani MD, Madhi SA, Singleton RJ et al (2010) Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet (London, England) 375(9725):1545–1555. https://doi.org/10.1016/S0140-6736(10)60206-1 [DOI: 10.1016/S0140-6736(10)60206-1]
  3. GBD 2013 Mortality and Causes of Death Collaborators (2015) Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385(9963):117–171. https://doi.org/10.1016/S0140-6736(14)61682-2 [DOI: 10.1016/S0140-6736(14)61682-2]
  4. Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Gill CJ et al (2022) Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet 399(10340):2047–2064. https://doi.org/10.1016/S0140-6736(22)00478-0 [DOI: 10.1016/S0140-6736(22)00478-0]
  5. GBD 2019 Diseases and Injuries Collaborators (2020) Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 396(10258):1204–1222. https://doi.org/10.1016/S0140-6736(20)30925-9 [DOI: 10.1016/S0140-6736(20)30925-9]
  6. Wang H, Abbas KM, Abbasifard M et al (2020) Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the global burden of disease study 2019. Lancet 396:1160–1203. https://doi.org/10.1016/S0140-6736(20)30977-6 [DOI: 10.1016/S0140-6736(20)30977-6]
  7. Branche AR, Falsey AR (2015) Respiratory syncytial virus infection in older adults: an under-recognized problem. Drugs Aging 32(4):261–269. https://doi.org/10.1007/s40266-015-0258-9 [DOI: 10.1007/s40266-015-0258-9]
  8. Chemaly RF, Shah DP, Boeckh MJ (2014) Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies. Clin Infect Dis 59(5):344–351. https://doi.org/10.1093/cid/ciu623 [DOI: 10.1093/cid/ciu623]
  9. Boeckh M, Englund J, Li Y, Miller C, Cross A, Fernandez H et al (2007) Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. Clin Infect Dis 44(2):245–249. https://doi.org/10.1086/509930 [DOI: 10.1086/509930]
  10. Garegnani L, Styrmisdóttir L, Rodriguez PR, Liquitay CME, Esteban I, Juan Va Franco JV (2021) Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children. Cochrane Database Syst Rev 11:CD013757.  https://doi.org/10.1002/14651858.CD013757.pub2 [DOI: 10.1002/14651858.CD013757.pub2]
  11. Garlapati S, Garg R, Brownlie R, Latimer L, Simko E, Hancock REW et al (2012) Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles. Vaccine 30(35):5206–5214. https://doi.org/10.1016/j.vaccine.2012.06.011 [DOI: 10.1016/j.vaccine.2012.06.011]
  12. GBD 2015 LRI Collaborators (2017) Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Infect Dis 17(11):1133–1161. https://doi.org/10.1016/S1473-3099(17)30396-1 [DOI: 10.1016/S1473-3099(17)30396-1]
  13. Geoghegan S, Erviti A, Caballero MT et al (2017) Mortality due to respiratory syncytial virus Burden and risk factors. Am J Respir Crit Care Med 195(1):96–103. https://doi.org/10.1164/rccm.201603-0658OC [DOI: 10.1164/rccm.201603-0658OC]
  14. Carbonell-Estrany X, Simões EAF, Bont L, Gentile A, Homaira N, Scotta MC et al (2022) Identifying the research, advocacy, policy and implementation needs for the prevention and management of respiratory syncytial virus lower respiratory tract infection in low- and middle-income countries. Front Pediatr 10:1033125.  https://doi.org/10.3389/fped.2022.1033125 [DOI: 10.3389/fped.2022.1033125]
  15. Simoes EA, Carbonell-Estrany X (2003) Impact of severe disease caused by respiratory syncytial virus in children living in developed countries. Pediatr Infect Dis J 13(8):18–20. https://doi.org/10.1097/01.inf.0000053881.47279.d9 [DOI: 10.1097/01.inf.0000053881.47279.d9]
  16. Luna MS, Manzoni P, Paes B, Baraldi E, Cossey V, Kugelman A et al (2020) Expert consensus on palivizumab use for respiratory syncytial virus in developed countries. Paediatr Respir Rev 33(35):44. https://doi.org/10.1016/j.prrv.2018.12.001 [DOI: 10.1016/j.prrv.2018.12.001]
  17. Reeves RM, van Wijhe M, Lehtonen T et al (2022) A systematic review of European clinical practice guidelines for respiratory syncytial virus (RSV) prophylaxis. J Infect Dis 226(Suppl 1):S110–S116.  https://doi.org/10.1093/infdis/jiac059 [DOI: 10.1093/infdis/jiac059]
  18. Flaxman AD, Vos T, Murray CJL  (2015)  An integrative metaregression framework for descriptive epidemiology. University of Washington Press
  19. Mazur NI, Löwensteyn YN, Willemsen JE, Gill CJ, Forman L, Mwananyanda LM et al (2021) Global respiratory syncytial virus–related infant community deaths. Clin Infect Dis 73(Suppl 3):S229–S237. https://doi.org/10.1093/cid/ciab528 [DOI: 10.1093/cid/ciab528]
  20. Carbonell-Estrany X, Rodgers-Gray BS, Paes B (2021) Challenges in the prevention or treatment of RSV with emerging new agents in children from low- and middleincome countries. Expert Rev Anti Infect Ther 19(4):419–441. https://doi.org/10.1080/14787210.2021.1828866 [DOI: 10.1080/14787210.2021.1828866]

MeSH Term

Child
Humans
Global Burden of Disease
Respiratory Syncytial Viruses
Quality-Adjusted Life Years
Respiratory Tract Infections
Global Health
Journal Article
Article has an altmetric score of 4

Word Cloud

Similar Articles

Cited By